News Related to Ado-Trastuzumab Emtansine

Related coverage linked through entity extraction aliases.

T-DXd Reshapes Treatment Sequencing in HER2-Positive Metastatic Breast Cancer

Mar 21, 2026

Trastuzumab deruxtecan is moving into earlier treatment lines for HER2-positive metastatic breast cancer, demonstrating superior efficacy over standard regimens and prompting reconsideration of long-standing treatment sequences.

CD47 Expression Levels Predict Response to Evorpacept Plus Zanidatamab in HER2+ Breast Cancer

Mar 11, 2026

Exploratory analysis from a phase 1/2 trial shows CD47 expression levels predict response to evorpacept plus zanidatamab in heavily pretreated HER2-positive metastatic breast cancer patients, supporting biomarker-driven patient selection.